MCK241108C610000
- 5.30
- +3.97+298.50%
McKesson Newsroom
Press Release: McKesson Corporation Reports Fiscal 2025 Second Quarter Results and Raises Full Year Adjusted EPS Guidance
Nasdaq 100 Extends Record Levels Ahead Of Fed Meeting, Tesla Hits 26-Month Highs, Small Caps Stall: What's Driving Markets Thursday?
McKesson Shares Jump After FY25 Outlook Boost, Strong 2Q Sales
Express News | Mckesson Shares up 10.5% After Co Raises Annual Profit Forecast
HubSpot Posts Better-Than-Expected Results, Joins Under Armour, Lyft, Wolverine World Wide, Zillow And Other Big Stocks Moving Higher On Thursday
McKesson Up Over 8%, on Pace for Largest Percent Increase Since March 2020 -- Data Talk
Mizuho Adjusts Price Target on McKesson to $550 From $530, Maintains Neutral Rating
These Analysts Boost Their Forecasts On McKesson Following Upbeat Earnings
McKesson Is Maintained at Outperform by Evercore ISI Group
BofA Securities Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $635
Evercore Maintains McKesson(MCK.US) With Buy Rating, Raises Target Price to $680
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
McKesson Upgraded at Baird on Core Ventures Deal After Q2 Beat
A Quick Look at Today's Ratings for McKesson(MCK.US), With a Forecast Between $535 to $688
This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Express News | Mckesson Corp : Leerink Partners Raises Target Price to $667 From $630
McKesson Analyst Ratings
U.S. stock market anomaly | McKesson rose more than 7% in pre-market trading, Q2 fiscal year 25 performance exceeded expectations, increasing share buybacks to $3.2 billion.
Gelonghui November 7th | Pharmaceutical giant MCK.US rose 7.2% to $588.9 before the market. In terms of news, the company's adjusted eps for the second quarter of 2025 was $7.07, exceeding the estimated $6.88, with sales of $93.7 billion, exceeding the estimated $89.33 billion. The company raised its performance expectations for the 2025 fiscal year, demonstrating confidence in sustained solid performance. Additionally, the company raised its full-year share repurchase target from $2.8 billion to $3.2 billion. (Gelonghui)
Barclays Remains a Buy on McKesson (MCK)
Analysts Conflicted on These Healthcare Names: Ultragenyx Pharmaceutical (RARE), Henry Schein (HSIC) and McKesson (MCK)